EVERSUN: A PHASE 2 TRIAL OF EVEROLIMUS ALTERNATING WITH SUNITINIB AS FIRST-LINE THERAPY FOR ADVANCED RENAL CELL CARCINOMA (ANZUP TRIAL 0901)

被引：0
|
作者：
Davis, I. D. [1 ]
Long, A. [2 ,13 ]
Martin, A. [2 ,13 ]
Espinoza, D. [2 ,13 ]
Yip, S. [2 ,13 ]
Thompson, J. F. [2 ]
Kichenadasse, G. [3 ]
Harrison, M. [4 ]
Lowenthal, R. M. [6 ]
Pavlakis, N. [5 ]
Azad, A. [7 ]
Kannourakis, G. [8 ]
Steer, C. [9 ]
Goldstein, D. [10 ]
Shapiro, J. [11 ]
Stockler, M. R. [2 ,4 ,12 ,13 ]
机构：
[1] Monash Univ, Eastern Hlth Clin Sch, Melbourne, Vic 3004, Australia
[2] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia
[3] Flinders Med Ctr, Adelaide, SA, Australia
[4] Royal Prince Alfred Hosp, Sydney, NSW, Australia
[5] Univ Sydney, Royal N Shore Hosp, Sydney, NSW 2006, Australia
[6] Royal Hobart Hosp, Hobart, Tas, Australia
[7] Austin Hlth, Melbourne, Vic, Australia
[8] Ballarat Oncol & Haematol Serv, Ballarat, Vic, Australia
[9] Border Med Oncol, Wodonga, Vic, Australia
[10] Univ New S Wales, Prince Wales Hosp, Sydney, NSW, Australia
[11] Cabrini Inst, Melbourne, Vic, Australia
[12] Concord Canc Ctr, Concord, NSW, Australia
[13] Sydney Catalyst Translat Canc Res Ctr, Sydney, NSW, Australia
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/j.ejca.2014.03.255
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P0211
引用
收藏
页码：E68 / E69
页数：2
相关论文
共 50 条
  • [21] Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance)
    Chen, Ronald C.
    Choueiri, Toni K.
    Feuilly, Marion
    Meng, Jie
    Lister, Johanna
    Marteau, Florence
    Falchook, Aaron D.
    Morris, Michael J.
    George, Daniel J.
    Feldman, Darren R.
    CANCER, 2020, 126 (24) : 5311 - 5318
  • [22] Dosing schedules and outcomes in patients with first-line sunitinib for advanced renal cell carcinoma
    Kitamura, Hiroshi
    Inoue, Ryuta
    Shindo, Tetsuya
    Nishiyama, Naotaka
    Masumori, Naoya
    ANNALS OF ONCOLOGY, 2015, 26 : 102 - 102
  • [23] Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
    Vazquez, Sergio
    Leon, Luis
    Fernandez, Ovidio
    Lazaro, Martin
    Grande, Enrique
    Aparicio, Luis
    ADVANCES IN THERAPY, 2012, 29 (03) : 202 - 217
  • [24] Phase I trial sunitinib plus everolimus in patients with metastatic renal cell carcinoma (mRCC)
    Molina, A. M.
    Feldman, D. R.
    Ginsberg, M. S.
    Fischer, P.
    Trinos, M. J.
    Patil, S.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [25] Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
    Sergio Vázquez
    Luis León
    Ovidio Fernández
    Martín Lázaro
    Enrique Grande
    Luis Aparicio
    Advances in Therapy, 2012, 29 : 202 - 217
  • [26] ALTER-UC-001: Phase II trial of anlotinib plus everolimus as first-line treatment for advanced non-clear cell renal cell carcinoma
    Zhang, Hailiang
    Ye, Ding-Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma
    Hainsworth, John D.
    Spigel, David R.
    Burris, Howard A., III
    Waterhouse, David
    Clark, Bobby L.
    Whorf, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2131 - 2136
  • [28] A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.
    Motzer, Robert J.
    Grunwald, Viktor
    Hutson, Thomas E.
    Porta, Camillo
    Powles, Thomas
    Eto, Masatoshi
    Dutcus, Corina E.
    Baig, Mahadi Ali
    Dutta, Lea
    Li, Di
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [29] A Phase 2 Trial of Sunitinib in Patients with Advanced Non-clear Cell Renal Cell Carcinoma
    Tannir, Nizar M.
    Plimack, Elizabeth
    Chaan Ng
    Tamboli, Pheroze
    Bekele, Nebiyou B.
    Xiao, Lianchun
    Smith, Lisa
    Lim, Zita
    Pagliaro, Lance
    Araujo, John
    Aparicio, Ana
    Matin, Surena
    Wood, Christopher G.
    Jonasch, Eric
    EUROPEAN UROLOGY, 2012, 62 (06) : 1013 - 1019
  • [30] A Phase III Trial to Compare Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab vs Sunitinib Alone in First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma (RCC)
    Motzer, Robert J.
    Grunwald, Viktor
    Hutson, Thomas E.
    Porta, Camillo
    Powles, Thomas
    Eto, Masatoshi
    Dutcus, Corina
    Baig, Mahadi A.
    Dutta, Lea
    Li, Di
    Young, Louise
    Choueiri, Toni K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 169 - 169
12345